Avonex clinical trials
Avonex is named as an intervention in 6 current clinical trials in our Germany, Spain, Australia, France, Italy, USA, Ireland, Netherlands, Belgium, Switzerland, Czechia, Portugal, Canada, Israel, UK, Turkey, India, Japan, Poland, Austria, Brazil, Mexico and Sweden registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Biogen (2). The most-studied condition is Multiple Sclerosis.
Where Avonex is approved
All regulators →Of the three regulators tracked here, the first to approve Avonex was the US, on 17 May 1996. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Avonex
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
NICE appraisals of Avonex
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Avonex. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Beta interferons and glatiramer acetate for treating multiple sclerosis NICE TA527 | Recommended Not recommended | 27 Jun 2018 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Avonex
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- EU
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Avonex
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Avonex
11 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Biogen | 2 |
| UMC Utrecht | 1 |
| Novartis Pharmaceuticals | 1 |
| German Society for Pediatric Oncology and Hematology GPOH gGmbH | 1 |
| Bayer | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Avonex trials
How many clinical trials are testing Avonex?
6 current trials in our Germany, Spain, Australia, France, Italy, USA, Ireland, Netherlands, Belgium, Switzerland, Czechia, Portugal, Canada, Israel, UK, Turkey, India, Japan, Poland, Austria, Brazil, Mexico and Sweden registers name Avonex (also registered as Interferon beta-1a) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Avonex trials recruiting patients?
Yes. 3 of the 6 trials are recruiting: 3 with sites in Germany, 2 with sites in Spain, 2 with sites in Australia, 1 with sites in France, 1 with sites in Italy, 1 with sites in USA, 2 with sites in Ireland, 1 with sites in Netherlands, 1 with sites in Belgium, 2 with sites in Switzerland, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Canada, 1 with sites in Israel, 1 with sites in UK, 1 with sites in India and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Avonex clinical trials?
Biogen (2), UMC Utrecht (1), Novartis Pharmaceuticals (1) and German Society for Pediatric Oncology and Hematology GPOH gGmbH (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Avonex clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Avonex works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Avonex works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Avonex (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.